These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 32345647)

  • 1. FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models.
    Lakins MA; Koers A; Giambalvo R; Munoz-Olaya J; Hughes R; Goodman E; Marshall S; Wollerton F; Batey S; Gliddon D; Tuna M; Brewis N
    Clin Cancer Res; 2020 Aug; 26(15):4154-4167. PubMed ID: 32345647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity.
    Huang PL; Kan HT; Hsu CH; Hsieh HT; Cheng WC; Huang RY; You JJ
    J Transl Med; 2023 May; 21(1):346. PubMed ID: 37226226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity.
    Kraman M; Faroudi M; Allen NL; Kmiecik K; Gliddon D; Seal C; Koers A; Wydro MM; Batey S; Winnewisser J; Young L; Tuna M; Doody J; Morrow M; Brewis N
    Clin Cancer Res; 2020 Jul; 26(13):3333-3344. PubMed ID: 32299814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1-Directed 4-1BB Activation.
    Yuwen H; Wang H; Li T; Ren Y; Zhang YK; Chen P; Sun A; Bian G; Li B; Flowers D; Presler M; Subramanian K; Xue J; Wang J; Lynch K; Mei J; He X; Shan B; Hou B
    Cancer Res; 2024 May; 84(10):1680-1698. PubMed ID: 38501978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity.
    Cheng LS; Zhu M; Gao Y; Liu WT; Yin W; Zhou P; Zhu Z; Niu L; Zeng X; Zhang D; Fang Q; Wang F; Zhao Q; Zhang Y; Shen G
    Cell Mol Biol Lett; 2023 May; 28(1):47. PubMed ID: 37259060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
    Knudson KM; Hicks KC; Ozawa Y; Schlom J; Gameiro SR
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
    Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
    Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
    Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Bispecific Antibody with PD-L1-assisted OX40 Activation for Cancer Treatment.
    Kuang Z; Pu P; Wu M; Wu Z; Wang L; Li Y; Zhang S; Jing H; Wu W; Chen B; Liu J
    Mol Cancer Ther; 2020 Dec; 19(12):2564-2574. PubMed ID: 32999045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy.
    Vitale LA; He LZ; Thomas LJ; Wasiuk A; O'Neill T; Widger J; Crocker A; Mills-Chen L; Forsberg E; Weidlick J; Patterson C; Hammond RA; Boyer J; Sisson C; Alvarado D; Goldstein J; Marsh HC; Keler T
    Cancer Immunol Immunother; 2020 Oct; 69(10):2125-2137. PubMed ID: 32451681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
    Muth ST; Saung MT; Blair AB; Henderson MG; Thomas DL; Zheng L
    Cancer Lett; 2021 Feb; 499():99-108. PubMed ID: 33271264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation.
    Muik A; Altintas I; Gieseke F; Schoedel KB; Burm SM; Toker A; Salcedo TW; Verzijl D; Eisel D; Grunwitz C; Kranz LM; Vormehr M; Satijn DPE; Diken M; Kreiter S; Sasser K; Ahmadi T; Türeci Ö; Breij ECW; Jure-Kunkel M; Sahin U
    Oncoimmunology; 2022; 11(1):2030135. PubMed ID: 35186440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer.
    Zhai T; Wang C; Xu Y; Huang W; Yuan Z; Wang T; Dai S; Peng S; Pang T; Jiang W; Huang Y; Zou Y; Xu Y; Sun J; Gong X; Zhang J; Tsun A; Li B; Miao X
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers.
    Yi M; Niu M; Zhang J; Li S; Zhu S; Yan Y; Li N; Zhou P; Chu Q; Wu K
    J Hematol Oncol; 2021 Sep; 14(1):146. PubMed ID: 34526097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner.
    Peper-Gabriel JK; Pavlidou M; Pattarini L; Morales-Kastresana A; Jaquin TJ; Gallou C; Hansbauer EM; Richter M; Lelievre H; Scholer-Dahirel A; Bossenmaier B; Sancerne C; Riviere M; Grandclaudon M; Zettl M; Bel Aiba RS; Rothe C; Blanc V; Olwill SA
    Clin Cancer Res; 2022 Aug; 28(15):3387-3399. PubMed ID: 35121624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific Antibody PD-L1 x CD3 Boosts the Anti-Tumor Potency of the Expanded Vγ2Vδ2 T Cells.
    Yang R; Shen S; Gong C; Wang X; Luo F; Luo F; Lei Y; Wang Z; Xu S; Ni Q; Xue Y; Fu Z; Zeng L; Fang L; Yan Y; Zhang J; Gan L; Yi J; Zhou P
    Front Immunol; 2021; 12():654080. PubMed ID: 34040604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a c-MET x CD137 bispecific antibody for targeted immune agonism in cancer immunotherapy.
    Zhang H; Wang Q; Yalavarthi S; Pekar L; Shamnoski S; Hu L; Helming L; Zielonka S; Xu C
    Cancer Treat Res Commun; 2024; 39():100805. PubMed ID: 38492435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1.
    Yi M; Zhang J; Li A; Niu M; Yan Y; Jiao Y; Luo S; Zhou P; Wu K
    J Hematol Oncol; 2021 Feb; 14(1):27. PubMed ID: 33593403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.
    Kvarnhammar AM; Veitonmäki N; Hägerbrand K; Dahlman A; Smith KE; Fritzell S; von Schantz L; Thagesson M; Werchau D; Smedenfors K; Johansson M; Rosén A; Åberg I; Winnerstam M; Nyblom E; Barchan K; Furebring C; Norlén P; Ellmark P
    J Immunother Cancer; 2019 Apr; 7(1):103. PubMed ID: 30975201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Combination Strategies for the A
    Voronova V; Peskov K; Kosinsky Y; Helmlinger G; Chu L; Borodovsky A; Woessner R; Sachsenmeier K; Shao W; Kumar R; Pouliot G; Merchant M; Kimko H; Mugundu G
    Front Immunol; 2021; 12():617316. PubMed ID: 33737925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.